Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 35 - Antineoplastic agents
Patents for A61P 35 - Antineoplastic agents (221,099)
10/2008
10/29/2008CN100429210C Substituted 6h-dibenzo[c,h]chromenes as estrogenic agents
10/29/2008CN100429201C Heterocyclic compounds and methods of use thereof
10/29/2008CN100428960C Method for preparing nano liver-target biodegradating medicine carrier material
10/29/2008CN100428959C Process for producing drug ultramicroparticle and apparatus therefor
10/29/2008CN100428949C Anticancer taxad Chinese medicine prepn
10/29/2008CN100428945C Preparation method of compound Chinese medicinal polysaccharide and its use
10/29/2008CN100428932C TGF-alpha expression inhibitors
10/28/2008US7442812 Substituted benzopyrans as selective estrogen receptor-beta agonists
10/28/2008US7442807 N-phenylpyrrole guanidine derivatives as melanocortin receptor ligands
10/28/2008US7442790 Caspase inhibitors and uses thereof
10/28/2008US7442784 For regulation of gene expression
10/28/2008US7442713 2-thio-substituted imidazole derivatives and their use in pharmaceutics
10/28/2008US7442708 Inhibitors of basic fibroblast growth factors (FGFs); treating cancer, rheumatoid arthritis, inflammatory bowel disease, cardiovascular disorders, diabetic retinopathy, achondroplasia, hypochondoplasia, or thanathophoric dysplasia
10/28/2008US7442700 N-[4-({4-[(5-methyl-1H-pyrazol-3-yl)amino]pyrrolo[2,1f][1,2,4]triazin-2-yl}sulfanyl)phenyl]cyclopropanecarboxamide; serine/threonine Aurora kinase inhibitor; anticarcinogenic agent; allergies and asthma, Alzheimer's disease, rheumatoid arthritis, autoimmune diseases, bone diseases, inflammation
10/28/2008US7442699 For treatment of rheumatoid arthritis, inflammatory or autoimmune condition, viral infection, cancer; 4-{[4-(4-chlorophenyl)pyrimidin-2-yl]amino}benzamide
10/28/2008US7442697 4-imidazolyl substituted pyrimidine derivatives with CDK inhibitory activity
10/28/2008US7442688 Composition and methods for the therapeutic use of an atonal-associated sequence for deafness, osteoarthritis and abnormal cell proliferation
10/28/2008US7442550 Detection is established by the fusogenic power of the polypeptide, which is demonstrated by syncytia formation; use in drug testing or drug screening; HERV-W envelope glycoprotein; cancer gene therapy
10/28/2008US7442546 Method of modulating inflammatory response
10/28/2008US7442524 Conjugate comprising polypeptide with N-glycosylation site and sugar; increase blood clot formation for treatment of thrombocytopenia and hemophilia
10/28/2008US7442386 Synthesis and use of reagents for improved DNA lipofection and/or slow release prodrug and drug therapies
10/28/2008CA2472107C Dibenzodiazepine derivates, their preparation and use
10/28/2008CA2423286C Amorphous form of cell cycle inhibitor
10/28/2008CA2417652C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
10/28/2008CA2403152C Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them
10/28/2008CA2235805C Anti-cancer agent
10/28/2008CA2225924C Recombinant mistletoe lectin
10/23/2008WO2008128189A1 Anti-cancer compositions and methods
10/23/2008WO2008128169A1 Sparc and methods of use thereof
10/23/2008WO2008128072A2 Axl kinase inhibitors useful for the treatment of cancer or hyperproliferative disorders
10/23/2008WO2008128063A1 Hydroquinone ansamycin formulations
10/23/2008WO2008128009A2 Aminopyrimidines useful as kinase inhibitors
10/23/2008WO2008127996A1 Methods and compositions for contributing to the treatment of cancers
10/23/2008WO2008127728A1 Biaryl compositions and methods for modulating a kinase cascade
10/23/2008WO2008127727A1 Biaryl compositions and methods for modulating a kinase cascade
10/23/2008WO2008127715A1 Carboline derivatives useful in the treatment of cancer and other diseases
10/23/2008WO2008127714A1 Administration of carboline derivatives useful in the treatment of cancer and other diseases
10/23/2008WO2008127712A1 Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
10/23/2008WO2008127710A2 Methods for treating cancer resistant to erbb therapeutics
10/23/2008WO2008127678A1 Pyrido [2, 3-d] pyrimidin-7-one compounds as inhibitors of pi3k-alpha for the treatment of cancer
10/23/2008WO2008127659A2 Anticancer combination of a dac inhibitor and a tyrosine kinase inhibitor
10/23/2008WO2008127594A2 Combination therapies comprising quinoxaline inhibitors of pi3k-alpha for use in the treatment of cancer
10/23/2008WO2008127199A1 Methods of controlling tumorigenesis and diagnosing the risk thereof
10/23/2008WO2008127197A1 Metal triangulo compound and methods of using the same
10/23/2008WO2008127193A1 Metalled sirnas for facilitated targeting of suboptimal mrna sequences
10/23/2008WO2008126918A1 Twelve-membered cyclomacrolactam derivative
10/23/2008WO2008126901A1 Nitrogen-containing heterocyclic compound and pharmaceutical composition containing the same
10/23/2008WO2008126847A1 Prophylactic or therapeutic agent for cancer
10/23/2008WO2008126732A1 Fused bicyclic heteroaryl derivatives
10/23/2008WO2008126413A1 Tem8 peptides and vaccines comprising the same
10/23/2008WO2008126398A1 Cytidine derivative-containing antitumor agent for continuous intravenous administration
10/23/2008WO2008126123A2 Water-soluble coronene derivatives active as inhibitors of telomerase
10/23/2008WO2008126002A2 Compound profiling method
10/23/2008WO2008125988A1 Novel derivatives of psammaplin a, a method for their synthesis and their use for the prevention or treatment of cancer
10/23/2008WO2008125839A2 Pyrimidine derivatives as inhibitors of phosphatidylinositol-3-kinase
10/23/2008WO2008125835A1 2-morpholin-4-yl-pyrimidines as pi3k inhibitors
10/23/2008WO2008125833A1 Pharmaceutical compounds
10/23/2008WO2008125820A1 Combination therapy comprising azd2171 and azd6244 or mek-inhibitor ii
10/23/2008WO2008125811A1 N-[HETEROARYLCARBONYL]-S-THIENYL-L-ALANINE DERIVATIVES AS α5β1 ANTAGONISTS
10/23/2008WO2008125800A2 Mmp activated vascular disrupting agents
10/23/2008WO2008125633A2 Egfr inhibitors for treatment and diagnosis of metastatic prostate cancer
10/23/2008WO2008125627A1 Pyridazine-, pyridine- and pyrane-derivatives as gpbar1 agonisis
10/23/2008WO2008125583A1 Ethynylated heterodinucleoside phosphate analogs, method for the production thereof, and use thereof
10/23/2008WO2008125487A1 Diphenyl-dihydro-imidazopyridinones
10/23/2008WO2008125215A1 Bicyclic and heterobicyclic derivatives, processes for preparing them and their uses
10/23/2008WO2008125014A1 Urea compounds, preparation methods and pharmaceutical uses thereof
10/23/2008WO2008124927A1 Sirna against thymidylate synthase and uses thereof in cancer treatment regimens
10/23/2008WO2008098129A3 Materials and methods for detecting and treating peritoneal ovarian tumor dissemination involving tissue transglutaminase
10/23/2008WO2008086783A3 Platinum complex
10/23/2008WO2008070350A9 Methods and compositions related to wrapping of dehydrons
10/23/2008WO2008060705A3 Anti-dll4 antibodies and methods using same
10/23/2008WO2008053330A3 Monoclonal antibodies against the human anti-mullerian hormone type ii receptor (amhr-ii)
10/23/2008WO2008049643A3 Gd2 peptide mimotopes for anticancer vaccination
10/23/2008WO2008024970A3 Tetrahydroindolone and tetrahydroindazolone derivatives
10/23/2008WO2008007113A3 Pharmaceutical combinations
10/23/2008WO2007134245A3 Elastin-like polymer delivery vehicles
10/23/2008WO2007095746A9 Cancerous disease modifying antibodies
10/23/2008WO2007062093A3 Combination therapy for the treatment of cancer comprising a metalloprotease inhibitor
10/23/2008US20080262202 Novel cancer-associated genes
10/23/2008US20080262099 Administering cannabidiol produced from a given cannabis chemovar and in the form of a botanical drug substance; modulators motility of glioma cell motility; uneffected by involvement of cannabinoid receptor antagonists; antitumor, anticarcinogenic, antiproliferative and antimetastsis agents.
10/23/2008US20080262078 Pharmaceutical Compositions
10/23/2008US20080262077 Pharmaceutical formulations containing lipoic acid derivatives
10/23/2008US20080262073 Pyrrolic Derivatives with Histone Deacetylase Inhibitory Activity
10/23/2008US20080262068 Method of Tonic Treatment With Oxyphenbutazone Derivatives
10/23/2008US20080262065 Novel inhibitors of glutaminyl cyclases
10/23/2008US20080262063 Novel inhibitors of glutaminyl cyclase
10/23/2008US20080262062 disease treatable with PARP modulators by identifying a level of PARP in a plurality of samples from a population, making a decision regarding identifying the disease treatable by the PARP modulators wherein the decision is made based on the level of PARP
10/23/2008US20080262051 5-(1,1-Difluoroethyl)-3-(4-{4-methyl-5-[2-(trifluoromethyl)phenyl]-4H-1,2,4-triazol-3-yl}bicyclo[2.2.2]oct-1-yl)-1,2,4-oxadiazole; inhibitors of the Sonic Hedgehog pathway; prostate, non-small cell lung cancers, gastrointestinal cancer and bladder cancer
10/23/2008US20080262049 Therapeutic Agent for Hematopoietic Tumor
10/23/2008US20080262045 N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}-4-(4-fluorophenoxy)benzenesulfonamide and N-{[(4S)-2,5-dioxoimidazolidinyl]methyl}[1,1'-biphenyl]-4-sulfonamide; chemical intermediates for enzyme inhibitors; especially as inhibitors of MMP12
10/23/2008US20080262042 1-[5-(2-Fluoropyridin-3-yl)-1-(phenylsulfonyl)-1H-pyrrol-3-yl]-N-methylmethanamine or a salt thereof; acid secretion inhibitor; potassium-competitive acid blocker
10/23/2008US20080262035 Amide Derivatives as Inhibitors of Histone Deacetylase
10/23/2008US20080262031 4-Aminoquinoline Derivatives as Antimalarials
10/23/2008US20080262028 Imidazole derivatives as inhibitors of tafia
10/23/2008US20080262021 [4-(8-Benzo[1,3]dioxol-5-yl-imidazo[4,5-c]quinolin-1-yl)-phenyl]-acetonitrile; treatment of chronic myeloic leukemia
10/23/2008US20080262020 6-(2-amino-1,3-thiazol-4-yl)-3-(2,4-dichlorophenyl)-1-methyl-1,9-dihydro-2H-pyrido[2,3-b]indol-2-one; affinity for GABAA-receptor-associated omega modulatory sites
10/23/2008US20080262014 Use of Camptothecin Derivatives for the Treatment of Proliferative Diseases in a Fixed Dosing Regimen
10/23/2008US20080262010 dissolving with D-glucoronic acid in one or more solvents; and precipitating one crystalline polymorph as the D-glucoronate salt; kinase-inhibiting
10/23/2008US20080262009 dissolving an amount of compound and acetic acid as a mixture, in one or more solvents; and precipitating one crystalline polymorph of the compound as the acetate salt from the mixture
10/23/2008US20080262008 useful for inhibiting protein kinase activity; heating an amount of one crystalline polymorph of the compound of formula I as the pharmaceutically acceptable salt to a temperature that converts it to a different crystalline polymorph
1 ... 900 901 902 903 904 905 906 907 908 909 910 911 912 913 914 915 916 917 918 919 920 ... 2211